Lilly and Novo name the GLP-1 molecules getting new data at EASD 2026

Eli Lilly and Novo Nordisk have both published lists of what they plan to present at the 62nd Annual Meeting of the European Association for the Study of Diabetes, held Sept. 28 to Oct. 2, 2026, in Milan, Italy ^[1][3]. The previews are mostly schedules and topic lists, but they confirm which drug programs will release fresh data in the next two weeks.

Lilly's Sept. 15 announcement highlights three programs: Foundayo (orforglipron), its once-daily oral non-peptide GLP-1 receptor agonist that is FDA-approved for chronic weight management; retatrutide, an investigational once-weekly GIP, GLP-1 and glucagon triple receptor agonist; and eloraTZP, an investigational combination of the selective amylin receptor agonist eloralintide with tirzepatide ^[1][2].

The eloraTZP Phase 2 results are the newest item on Lilly's list. They are scheduled for an EASD-sponsored amylin symposium on Wednesday, Sept. 30, from 4:30 to 5:30 p.m. CEST, in adults with obesity or overweight and type 2 diabetes ^[1]. Lilly has previously reported Phase 1 data in which adding eloralintide 3 mg to tirzepatide 5 mg produced 17% weight loss over 16 weeks, compared with 10% for tirzepatide 5 mg alone ^[1].

Other Lilly presentations restate results already announced. In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes taking retatrutide lost up to an average of 49.6 pounds (22.5 kg, or 20.8%) and lowered A1C by up to an average of 1.6% at 80 weeks ^[1]. In ACHIEVE-4, Foundayo was non-inferior to insulin glargine, with a 16% lower risk of MACE-4 events (hazard ratio 0.84; 95% CI 0.59 to 1.20) and a 23% lower risk of MACE-3 events (HR 0.77; 95% CI 0.52 to 1.13) ^[1]. SURPASS-CVOT showed Mounjaro (tirzepatide) was non-inferior to Trulicity, with an 8% lower risk of MACE-3 events (HR 0.92; 95.3% CI 0.83 to 1.01) ^[1]. New analyses include a time-to-goal comparison in which Foundayo 17.2 mg helped people reach A1C and weight-loss goals faster than dapagliflozin and oral semaglutide 7 mg and 14 mg, and exploratory blood-protein findings from the head-to-head SURMOUNT-5 trial of Zepbound versus semaglutide ^[1].

What Novo is bringing

Novo Nordisk said on Sept. 16 that it will present 44 abstracts covering semaglutide, CagriSema and zenagamtide ^[3]. The one closest to everyday use is the OCTANE real-world US study, a short oral discussion on Wednesday, Sept. 30, reporting three-month weight outcomes among people with overweight or obesity who switched from injectable semaglutide or tirzepatide to oral semaglutide for weight management ^[3].

Novo will also show CagriSema data from REIMAGINE-1 on body composition and on the share of participants hitting combined A1C and weight targets, plus functional MRI work on appetite, eating behavior and brain responses to food cues ^[3]. Phase 2b results for zenagamtide (formerly amycretin), a single molecule that acts on both GLP-1 and amylin receptors, are set for Wednesday, Sept. 30 ^[3]. A real-world analysis called COMPETE SWITCH CV will compare major adverse cardiovascular events in adults with type 2 diabetes who escalated to semaglutide 2.0 mg versus those who switched to tirzepatide ^[3]. Novo cautions that accepted abstracts include preliminary data that may change in final published manuscripts ^[3].

Why it matters for patients

Most of what is in these previews is not new information; it is a calendar. Still, it narrows down where the next real numbers will come from. Two questions that matter for people weighing options are on the schedule: how oral semaglutide performs for weight in ordinary clinical practice rather than a trial, and whether pairing an amylin drug with tirzepatide adds meaningfully to weight loss.

None of these previews change what is available at a pharmacy today. Retatrutide, eloraTZP, eloralintide, zenagamtide and CagriSema are investigational and not approved. Neither company disclosed pricing, insurance coverage or US regulatory timing in these announcements, and Phase 2 results do not establish long-term safety.

What happens next

Lilly hosts an industry symposium on Monday, Sept. 28, from 10 a.m. to 4 p.m. CEST ^[1]. Novo's international press briefing is Wednesday, Sept. 30, available by webcast ^[3]. Retatrutide and Mounjaro symposia are also Sept. 30 at 8:30 a.m. CEST, with the Foundayo symposium on Thursday, Oct. 1, at 8:30 a.m. CEST ^[1]. Whether any of these datasets lead to new FDA filings has not been disclosed.